McKesson Corporation (NYSE: MCK) stands today as the undisputed titan of the U.S. pharmaceutical supply chain. While the company has long been a staple of the Fortune 500, its relevance has surged in early 2026 as it navigates a complex landscape of drug shortages, revolutionary new therapies, and a massive internal restructuring. The company is [...]
Healthcare distributor and services company Cardinal Health (NYSE:CAH) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 18.8% year on year to $65.63 billion. Its non-GAAP profit of $2.63 per share was 11.2% above analysts’ consensus estimates.
Shares of healthcare distributor and services company Cardinal Health (NYSE:CAH)
jumped 10.1% in the afternoon session after the company reported better-than-expected fourth-quarter financial results and raised its full-year earnings guidance.
Healthcare distributor and services company Cardinal Health (NYSE:CAH) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 18.8% year on year to $65.63 billion. Its non-GAAP profit of $2.63 per share was 11.2% above analysts’ consensus estimates.
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising
as the industry has posted a 22% gain over the past six months, beating the S&P 500 by 14.2 percentage points.
Wall Street has issued downbeat forecasts for the stocks in this article.
These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.
The global healthcare landscape shifted decisively on December 16, 2025, with the public market return of Medline Industries (Nasdaq: MDLN). After four years under the stewardship of a private equity consortium—and decades of private family ownership before that—the medical supply titan has reclaimed its status as a public entity in the largest U.S. initial public [...]
CRANFORD, NJ — As the 2025 calendar year draws to a close, Citius Oncology, Inc. (Nasdaq: CTOR) has reached a pivotal juncture in its corporate evolution. Following the release of its SEC 10-K filing for the fiscal year ended September 30, 2025, the company has officially shed its "development-stage" label, entering
In a stunning return to the public stage, Medline Industries (Nasdaq: MDLN) successfully executed the largest initial public offering (IPO) in the United States since 2021, pricing its shares at the top of its range and witnessing a massive first-day "pop" that has sent ripples through the financial world. The
Looking back on healthcare providers & services stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Cardinal Health (NYSE:CAH) and its peers.
While profitability is essential, it doesn’t guarantee long-term success.
Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
